Journal Article

Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS

  • Sasaki K
  • Jabbour E
  • Montalban-Bravo G
  • et al.
NEJM Evidence (2022) 1(10)
DOI: 10.1056/evidoa2200034
N/ACitations
Citations of this article
19Readers
Mendeley users who have this article in their library.
Get full text

Abstract

AbstractBackgroundThe hypomethylating agents are part of the standard of care in the treatment of myelodysplastic syndromes (MDS), but their role in patients with lower-risk disease is unclear.Meth...

Cite

CITATION STYLE

APA

Sasaki, K., Jabbour, E., Montalban-Bravo, G., Darbaniyan, F., Do, K.-A., Class, C., … Garcia-Manero, G. (2022). Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS. NEJM Evidence, 1(10). https://doi.org/10.1056/evidoa2200034

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free